| Compound | Disease | Phase |
|---|---|---|
| Rodatristat ethyl | Pulmonary Arterial Hypertension (PAH) | Phase 2 |
| Idiopathic Pulmonary Fibrosis (IPF) | Research | |
| ALTA-2530 | Transplant-associated bronchiolitis obliterans syndrome | IND Enabling |
| Chemical-induced bronchiolitis obliterans syndrome | Research | |
| Next-Generation TPH Inhibitors | Oral agents for multiple indications | Research |
| Alternative routes of administration for multiple indications | Research |
| Compound | Disease | Research | IND Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
|
a peripherally acting TPH inhibitor |
Pulmonary Arterial Hypertension (PAH) | |||||
| Idiopathic Pulmonary Fibrosis (IPF) | ||||||
|
a treatment for bronchiolitis obliterans syndrome and chemical lung injury |
Transplant-associated bronchiolitis obliterans syndrome | |||||
| Chemical-induced bronchiolitis obliterans syndrome |
Partnered with BARDA / NIAID |
|||||
|
Next-Generation TPH Inhibitors |
Oral agents for multiple indications | |||||
| Alternative routes of administration of multiple indications | ||||||